7.19
-0.16(-2.18%)
Currency In USD
| Previous Close | 7.35 |
| Open | 7.21 |
| Day High | 7.25 |
| Day Low | 6.75 |
| 52-Week High | 17.5 |
| 52-Week Low | 5.68 |
| Volume | 712,004 |
| Average Volume | 894,198 |
| Market Cap | 424.75M |
| PE | -2.17 |
| EPS | -3.32 |
| Moving Average 50 Days | 7.05 |
| Moving Average 200 Days | 7.99 |
| Change | -0.16 |
If you invested $1000 in Cullinan Oncology, Inc. (CGEM) since IPO date, it would be worth $240.39 as of November 09, 2025 at a share price of $7.19. Whereas If you bought $1000 worth of Cullinan Oncology, Inc. (CGEM) shares 3 years ago, it would be worth $620.36 as of November 09, 2025 at a share price of $7.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:11 PM GMT
CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate observed at clinically active target doses; initial do
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
GlobeNewswire Inc.
Oct 25, 2025 3:01 PM GMT
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerat
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
GlobeNewswire Inc.
Sep 12, 2025 11:00 AM GMT
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Jeffrey Jones, M.D., M.B.A., C